title: Prognostic factors in Hodgkin's lymphoma.
abstract: Risk-adapted treatment strategies have constituted a major issue since the beginning of clinical research into Hodgkin's disease (HD). Various prognostic factors have been identified and several of those considered for staging procedures, resulting in strictly stage-dependent treatment recommendations for patients suffering from HD. These factors may be subdivided in host-related (e.g. age, sex) and tumour-related (e.g. number of tumour cells, growth characteristics, spread of tumour cells, resistance to apoptosis) factors. Owing to the striking improvement of the overall prognosis in HD patients it may be difficult to identify novel prognostic factors analysing the minority of patients with a fatal outcome. However, especially in advanced-stage disease, improved treatment results were achieved by the introduction of more aggressive treatment regimens, resulting in an increased toxicity rate. Thus, partially in contrast to earlier work in this field, future prognostic factors are needed for identification of those patients that have a good prognosis and might be susceptible to overtreatment. During the Fifth International Symposium on Hodgkin's Lymphoma, promising results on several new prognostic markers were presented. Furthermore, a joint effort to design new studies on large, well characterised patient groups has been initiated.
authors.affiliation: Department of Internal Medicine I, University of Cologne, Germany.
authors.forename: T
authors.initials: T
authors.lastname: Zander
authors.forename: S
authors.initials: S
authors.lastname: Wiedenmann
authors.forename: J
authors.initials: J
authors.lastname: Wolf
mesh_terms: D014408:Biomarkers, Tumor / Q000378:metabolism; D003131:Combined Modality Therapy; D018450:Disease Progression; D006689:Hodgkin Disease / Q000175:diagnosis* / Q000473:pathology / Q000628:therapy; D006801:Humans; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D011379:Prognosis
chemical_list: D014408:Biomarkers, Tumor